## J Michael Mathis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/252683/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CXCL12 Retargeting of an Oncolytic Adenovirus Vector to the Chemokine CXCR4 and CXCR7 Receptors in Breast Cancer. Journal of Cancer Therapy, 2021, 12, 311-336.	0.1	4
2	<sup>177</sup> Lu-Labeled Eu-Doped Mesoporous SiO <sub>2</sub> Nanoparticles as a Theranostic Radiopharmaceutical for Colorectal Cancer. ACS Applied Nano Materials, 2020, 3, 8691-8701.	2.4	15
3	Cytotoxic Activity of the Mesoionic Compound MIH 2.4Bl in Breast Cancer Cell Lines. Breast Cancer: Basic and Clinical Research, 2020, 14, 117822342091333.	0.6	0
4	Mechanistic studies of cytotoxic activity of the mesoionic compound MIHÂ2.4Bl in MCF‑7 breast cancer cells. Oncology Letters, 2020, 20, 2291-2301.	0.8	4
5	Tumor-Targeting NIRF NanoGUMBOS with Cyclodextrin-Enhanced Chemo/Photothermal Antitumor Activities. ACS Applied Materials & Interfaces, 2019, 11, 27548-27557.	4.0	25
6	Surface modification strategy based on the conjugation of NaYF4:5%Eu luminescent nanoprobe with organic aromatic compounds for application in bioimaging assays. Journal of Nanoparticle Research, 2019, 21, 1.	0.8	2
7	Synthesis and investigation of phthalocyanine-biotin conjugates. Journal of Porphyrins and Phthalocyanines, 2019, 23, 125-135.	0.4	4
8	Synthesis, Characterization, and Evaluation of Near-IR Boron Dipyrromethene Bioconjugates for Labeling of Adenocarcinomas by Selectively Targeting the Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 2019, 62, 3323-3335.	2.9	28
9	Oncolytic Virotherapy for Breast Cancer Treatment. Current Gene Therapy, 2018, 18, 192-205.	0.9	28
10	Endocytic Selective Toxicity of Rhodamine 6G nanoGUMBOS in Breast Cancer Cells. Molecular Pharmaceutics, 2018, 15, 3837-3845.	2.3	16
11	The roles of oncogenic miRNAs and their therapeutic importance in breast cancer. European Journal of Cancer, 2017, 72, 1-11.	1.3	87
12	Single fiber surface enhanced Raman scattering probe. Journal of Vacuum Science and Technology B:Nanotechnology and Microelectronics, 2017, 35, 06GF01.	0.6	2
13	Experimental method and statistical analysis to fit tumor growth model using SPECT/CT imaging: a preclinical study. Quantitative Imaging in Medicine and Surgery, 2017, 7, 299-299.	1.1	7
14	CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter. Oncolytic Virotherapy, 2016, Volume 5, 99-113.	6.0	12
15	Syngeneic Syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting. Oncolmmunology, 2016, 5, e1136046.	2.1	17
16	IL27 controls skin tumorigenesis via accumulation of ETAR-positive CD11b cells in the pre-malignant skin. Oncotarget, 2016, 7, 77138-77151.	0.8	4
17	Characterization of an oncolytic adenovirus vector constructed to target the cMet receptor. Oncolytic Virotherapy, 2015, 4, 119.	6.0	6
18	Initial gene vector dosing for studying symptomatology of amyotrophic lateral sclerosis in nonâ€human primates. Journal of Medical Primatology, 2015, 44, 66-75.	0.3	6

#	Article	IF	CITATIONS
19	Construction and Radiolabeling of Adenovirus Variants that Incorporate Human Metallothionein into Protein IX for Analysis of Biodistribution. Molecular Imaging, 2014, 13, 7290.2014.00022.	0.7	5
20	Quantification of bone changes in a collagen-induced arthritis mouse model by reconstructed three dimensional micro-CT. Biological Procedures Online, 2013, 15, 8.	1.4	19
21	VEGF-A isoform modulation in an preclinical TNBS model of ulcerative colitis: protective effects of a VEGF164b therapy. Journal of Translational Medicine, 2013, 11, 207.	1.8	32
22	A Recombinant Inhibitory Isoform of Vascular Endothelial Growth Factor164/165 Aggravates Ischemic Brain Damage in a Mouse Model of Focal Cerebral Ischemia. American Journal of Pathology, 2013, 183, 1010-1024.	1.9	17
23	Selective Forelimb Impairment in Rats Expressing a Pathological TDP-43 25 kDa C-terminal Fragment to Mimic Amyotrophic Lateral Sclerosis. Molecular Therapy, 2013, 21, 1324-1334.	3.7	38
24	Phenothiazine Inhibitors of TLKs Affect Double-Strand Break Repair and DNA Damage Response Recovery and Potentiate Tumor Killing with Radiomimetic Therapy. Genes and Cancer, 2013, 4, 39-53.	0.6	33
25	Gut sterilization in experimental colitis leukocyte mediated colon injury, and effects on angiogenesis/lymphangiogenesis. Open Journal of Gastroenterology, 2013, 03, 12-24.	0.1	3
26	Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model. Surgery, 2012, 152, 441-448.	1.0	6
27	Effects of the tropical ginger compound,1'-acetoxychavicol acetate, against tumor promotion in K5.Stat3C transgenic mice. Journal of Experimental and Clinical Cancer Research, 2012, 31, 57.	3.5	9
28	Dendritic Cell Based PSMA Immunotherapy for Prostate Cancer Using a CD40-Targeted Adenovirus Vector. PLoS ONE, 2012, 7, e46981.	1.1	28
29	Metabolic Modulation of Cytokineâ€Induced Brain Endothelial Adhesion Molecule Expression. Microcirculation, 2012, 19, 155-165.	1.0	20
30	PET Imaging a MPTP-Induced Mouse Model of Parkinson's Disease Using the Fluoropropyl-Dihydrotetrabenazine Analog [18F]-DTBZ (AV-133). PLoS ONE, 2012, 7, e39041.	1.1	18
31	Establishment of a mammary carcinoma cell line from Syrian hamsters treated with N-methyl-N-nitrosourea. Cancer Letters, 2011, 312, 82-90.	3.2	8
32	Role of the endothelium in inflammatory bowel diseases. World Journal of Gastroenterology, 2011, 17, 578.	1.4	131
33	Gliovascular and cytokine interactions modulate brain endothelial barrier in vitro. Journal of Neuroinflammation, 2011, 8, 162.	3.1	32
34	Genetic Incorporation of Human Metallothionein into the Adenovirus Protein IX for Non-Invasive SPECT Imaging. PLoS ONE, 2011, 6, e16792.	1.1	11
35	Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface. Journal of Tissue Engineering and Regenerative Medicine, 2010, 4, 247-258.	1.3	37
36	Effects of ATRA combined with citrus and ginger-derived compounds in human SCC xenografts. BMC Cancer, 2010, 10, 394.	1.1	12

#	Article	IF	CITATIONS
37	Aggressive mammary carcinoma progression in Nrf2 knockout mice treated with 7,12-dimethylbenz[a]anthracene. BMC Cancer, 2010, 10, 540.	1.1	60
38	Angiopoietin-2 in experimental colitis. Inflammatory Bowel Diseases, 2010, 16, 1029-1039.	0.9	67
39	Association of coreâ€binding factor β with the malignant phenotype of prostate and ovarian cancer cells. Journal of Cellular Physiology, 2010, 225, 875-887.	2.0	24
40	MURINE rVEGF164b, AN INHIBITORY VEGF REDUCES VEGF-A DEPENDENT ENDOTHELIAL PROLIFERATION AND BARRIER DYSFUNCTION. Microcirculation, 2010, 17, no-no.	1.0	12
41	Substitution of Adenovirus Serotype 3 Hexon onto a Serotype 5 Oncolytic Adenovirus Reduces Factor X Binding, Decreases Liver Tropism, and Improves Antitumor Efficacy. Molecular Cancer Therapeutics, 2010, 9, 2536-2544.	1.9	48
42	Differential Cytokine Responses in Human and Mouse Lymphatic Endothelial Cells to Cytokines <i>in Vitro</i> . Lymphatic Research and Biology, 2010, 8, 155-164.	0.5	51
43	The Utility of a Tissue Slice Model System to Determine Breast Cancer Infectivity by Oncolytic Adenoviruses. Journal of Surgical Research, 2010, 163, 270-275.	0.8	16
44	Effect of B7.1 Costimulation on T-Cell Based Immunity against TAP-Negative Cancer Can Be Facilitated by TAP1 Expression. PLoS ONE, 2009, 4, e6385.	1.1	4
45	Mixed isotope effects: Image quality in multimodality PET/SPECT preclinical imaging. , 2009, , .		1
46	Priming of immune responses against transporter associated with antigen processing (TAP)â€deficient tumours: tumour direct priming. Immunology, 2009, 128, 420-428.	2.0	8
47	Promotion of incisional wound repair by human mesenchymal stem cell transplantation. Experimental Dermatology, 2009, 18, 362-369.	1.4	117
48	Tissue microarray analysis of eIF4E and its downstream effector proteins in human breast cancer. Journal of Experimental and Clinical Cancer Research, 2009, 28, 5.	3.5	24
49	Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control. Breast Cancer Research and Treatment, 2008, 108, 43-55.	1.1	34
50	Mesenchymal Stem Cells Effectively Deliver an Oncolytic Adenovirus to Intracranial Glioma. Stem Cells, 2008, 26, 831-841.	1.4	226
51	elF4E-Targeted Suicide Gene Therapy in a Minimal Residual Mouse Model for Metastatic Soft-Tissue Head and Neck Squamous Cell Carcinoma Improves Disease-Free Survival. Journal of Surgical Research, 2008, 148, 83-89.	0.8	9
52	In vivo Survivors of Transformed Mouse Ovarian Surface Epithelial Cells Display Diverse Phenotypes for Gene Expression and Tumorigenicity. Tumor Biology, 2008, 29, 359-370.	0.8	3
53	Trogocytosis of MHC-I/Peptide Complexes Derived from Tumors and Infected Cells Enhances Dendritic Cell Cross-Priming and Promotes Adaptive T Cell Responses. PLoS ONE, 2008, 3, e3097.	1.1	41
54	Interaction of microsatellite instability and loss of heterozygosity in adenocarcinoma: multiple markers in adenocarcinoma: an introduction to â€~Genetic changes in Slovenian patients with gastric adenocarcinoma evaluated in terms of microsatellite DNA'. European Journal of Gastroenterology and Hepatology, 2007, 19, 1038-1040.	0.8	1

#	Article	IF	CITATIONS
55	Rat Adenocarcinoma Cell Line Infected With an Adenovirus Carrying a Novel Herpes-Simplex Virus-Thymidine Kinase Suicide Gene Construct Dies by Apoptosis Upon Treatment with Ganciclovir. Journal of Surgical Research, 2007, 143, 189-194.	0.8	12
56	Elevated Levels of Chemokine Receptor CXCR4 in HER-2 Negative Breast Cancer Specimens Predict Recurrence. Journal of Surgical Research, 2007, 141, 53-59.	0.8	52
57	Combining high selectivity of replicationviaCXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer. International Journal of Cancer, 2007, 120, 935-941.	2.3	12
58	A novel suicide gene therapy targeting the overexpression of eukaryotic initiation factor 4E improves survival in a rat peritoneal carcinomatosis model. Surgery, 2007, 142, 270-275.	1.0	2
59	HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. Toxicology and Applied Pharmacology, 2007, 224, 60-71.	1.3	68
60	Effect of adenoviral mediated overexpression of fibromodulin on human dermal fibroblasts and scar formation in full-thickness incisional wounds. Journal of Molecular Medicine, 2007, 85, 481-496.	1.7	51
61	Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Research and Treatment, 2007, 105, 157-167.	1.1	194
62	Genetic Incorporation of a Herpes Simplex Virus Type 1 Thymidine Kinase and Firefly Luciferase Fusion into the Adenovirus Protein IX for Functional Display on the Virion. Molecular Imaging, 2006, 5, 7290.2006.00029.	0.7	48
63	Specific and nontoxic silencing in mammalian cells with expressed long dsRNAs. Nucleic Acids Research, 2006, 34, 3803-3810.	6.5	17
64	Strategies to enhance transductional efficiency of adenoviral-based gene transfer to primary human fibroblasts and keratinocytes as a platform in dermal wounds. Wound Repair and Regeneration, 2006, 14, 608-617.	1.5	16
65	Employment of liver tissue slice analysis to assay hepatotoxicity linked to replicative and nonreplicative adenoviral agents. Cancer Gene Therapy, 2006, 13, 606-618.	2.2	21
66	Cancer-specific targeting of an adenovirus-delivered herpes simplex virus thymidine kinase suicide gene using translational control. Journal of Gene Medicine, 2006, 8, 1105-1120.	1.4	33
67	Advanced Generation Adenoviral Virotherapy Agents Embody Enhanced Potency Based upon CAR-Independent Tropism: Fig. 1 Clinical Cancer Research, 2006, 12, 2651-2656.	3.2	11
68	836. Changes in Maturation Profiles of Dendritic Cells Transduced with a CD40-Targeted Adenoviral Vector. Molecular Therapy, 2006, 13, S323.	3.7	0
69	843. MicroPET Imaging of HSV-TK Activity To Assess Cancer-Specific Gene Expression Targeted at the Level of Protein Translation Initiation. Molecular Therapy, 2006, 13, S326.	3.7	Ο
70	Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion. Molecular Imaging, 2006, 5, 510-9.	0.7	35
71	Gene transfer to carcinoma of the breast with fiber-modified adenoviral vectors in a tissue slice model system. Cancer Biology and Therapy, 2005, 4, 1203-1210.	1.5	31
72	Oncolytic adenoviruses – selective retargeting to tumor cells. Oncogene, 2005, 24, 7775-7791.	2.6	111

#	Article	IF	CITATIONS
73	Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion. Virology, 2005, 338, 247-258.	1.1	59
74	Reversal of experimental colitis disease activity in mice following administration of an adenoviral IL-10 vector. Journal of Inflammation, 2005, 2, 13.	1.5	51
75	A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy. Gene Therapy, 2005, 12, 1696-1706.	2.3	38
76	Preclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model system. Breast Cancer Research, 2005, 7, R1141-52.	2.2	30
77	Profiling transcript levels for steroidogenic enzymes in fetal tissues. Journal of Steroid Biochemistry and Molecular Biology, 2003, 87, 181-189.	1.2	140
78	Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas. European Journal of Endocrinology, 2002, 147, 795-802.	1.9	58
79	IL-1β-induced production of metalloproteinases by synovial cells depends on gap junction conductance. American Journal of Physiology - Cell Physiology, 2002, 282, C1254-C1260.	2.1	24
80	Topotecan Concomitant with Primary Brachytherapy Radiation in Patients with Cervical Carcinoma: A Phase I Trial. Gynecologic Oncology, 2001, 80, 128-131.	0.6	13
81	Placebo-Controlled Trial of Indole-3-Carbinol in the Treatment of CIN. Gynecologic Oncology, 2000, 78, 123-129.	0.6	237
82	Evidence for Ovarian Granulosa Stem Cells: Telomerase Activity and Localization of the Telomerase Ribonucleic Acid Component in Bovine Ovarian Follicles1. Biology of Reproduction, 1999, 61, 358-366.	1.2	61
83	Efficacy of intraperitoneal adenovirus-mediated p53 gene therapy in ovarian cancer. International Journal of Gynecological Cancer, 1999, 9, 365-372.	1.2	12
84	In VivoStudies of Adenovirus-Based p53 Gene Therapy for Ovarian Cancer. Gynecologic Oncology, 1998, 69, 197-204.	0.6	31
85	Does Glutamine Supplementation Increase Radioresistance in Squamous Cell Carcinoma of the Cervix?. Gynecologic Oncology, 1998, 71, 359-363.	0.6	9
86	Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. Human Molecular Genetics, 1998, 7, 195-202.	1.4	158
87	Angiotensin II and Potassium Regulate Human CYP11B2 Transcription through Common cis-Elements. Molecular Endocrinology, 1997, 11, 638-649.	3.7	176
88	Ca <sup>2+</sup> -Regulated Expression of Aldosterone Synthase Is Mediated By Calmodulin and Calmodulin-Dependent Protein Kinases. Endocrinology, 1997, 138, 835-838.	1.4	65
89	Differential regulation of 11β-hydroxylase and aldosterone synthase in human adrenocortical H295R cells. Molecular and Cellular Endocrinology, 1996, 121, 87-91.	1.6	79
90	Immunologic characterization of tumor markers in human ovarian cancer cell lines. Journal of the Society for Gynecologic Investigation, 1996, 3, 216-222.	1.9	16

#	Article	IF	CITATIONS
91	Brain-derived neurotrophic factor induces functional expression and phenotypic differentiation of cultured fetal neuropeptide Y-producing neurons. Journal of Neuroscience Research, 1995, 42, 638-647.	1.3	35
92	Adenovirus-Based p53 Gene Therapy in Ovarian Cancer. Gynecologic Oncology, 1995, 59, 171-178.	0.6	73
93	Ovarian Tumors Display Persistent Microsatellite Instability Caused by Mutation in the Mismatch Repair Gene hMSH-2. Cold Spring Harbor Symposia on Quantitative Biology, 1994, 59, 349-356.	2.0	3
94	Genetic instability in human ovarian cancer cell lines Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 9495-9499.	3.3	129
95	Transformation of human granulosa cells with the E6 and E7 regions of human papillomavirus. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 705-710.	1.8	39
96	Angiotensin increases aldosterone synthase mRNA levels in human NCI-H295 cells. Molecular and Cellular Endocrinology, 1993, 94, R9-R13.	1.6	45
97	Brain 4: a novel mammalian POU domain transcription factor exhibiting restricted brain-specific expression EMBO Journal, 1992, 11, 2551-2561.	3.5	136
98	Calcium/calmodulin-dependent protein kinase mediates a pathway for transcriptional regulation Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 3710-3714.	3.3	110
99	Modulation of the Polycycuc Aromatic Hydrocarbon-Dependent Induction of Cytochrome P450ia1 By Glucocorticoids. Drug Metabolism Reviews, 1989, 20, 585-599.	1.5	7
100	Glucocorticoid regulation of the rat cytochrome P450c (P450IA1) gene: Receptor binding within intron I. Archives of Biochemistry and Biophysics, 1989, 269, 93-105.	1.4	74
101	Hormonal regulation of the xenobiotic metabolizing enzymes. Molecular and Cellular Endocrinology, 1988, 60, 105-108.	1.6	4
102	Identification of multiple regulatory elements on the human cytochrome P450IA1 gene. Carcinogenesis, 1988, 9, 1599-1605.	1.3	120
103	Regulation of cytochrome P-450c by glucocorticoids and polycyclic aromatic hydrocarbons in cultured fetal rat hepatocytes. Archives of Biochemistry and Biophysics, 1986, 246, 439-448.	1.4	48
104	Synergistic induction of monooxygenase activity by glucocorticoids and polycyclic aromatic hydrocarbons in human fetal hepatocytes in primary monolayer culture. Archives of Biochemistry and Biophysics, 1986, 244, 650-661.	1.4	33
105	Substrate-induced inactivation of argininosuccinate lyase by monofluorofumarate and difluorofumarate. Biochemistry, 1983, 22, 3729-3735.	1.2	8
106	Steroid 21-sulfatase activity in human placenta. The Journal of Steroid Biochemistry, 1983, 18, 575-579.	1.3	13
107	Ca2+-Regulated Expression of Aldosterone Synthase Is Mediated By Calmodulin and Calmodulin-Dependent Protein Kinases. , 0, .		19